Mounjaro Reduces Major Cardiovascular Events by 32% in New Study
A major new study published in The BMJ reveals that the diabetes and weight-loss drug Mounjaro reduces major adverse cardiovascular events by 32% compared to standard care in high-risk patients, driven largely by a significant drop in myocardial infarctions over a one-year monitoring period. The pursuit of modern cardiometabolic care has increasingly focused on whether … Read more